Advertisement
Share

U.S. to spend $3.2 billion on treatments for COVID-19 and other viral diseases

Anthony Fauci speaks into a microphone.
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, speaks May 11 at a hearing on Capitol Hill.
(Jim Lo Scalzo / Pool photo)

The United States is devoting $3.2 billion to speed development of antiviral pills to treat COVID-19 and other dangerous diseases that could turn into pandemics.

The new program will invest in “accelerating things that are already in progress” for COVID-19 but also would work to come up with treatments for other viral conditions, said Dr. Anthony Fauci, the nation’s top infectious disease expert. He announced the investment Thursday at a White House briefing.

“There are few treatments that exist for many of the viruses that have pandemic potential,” he said, including the ones that cause Ebola, dengue, West Nile and Middle East respiratory syndrome.

But he added, “vaccines clearly remain the centerpiece of our arsenal.”

Advertisement

The U.S. has approved one antiviral drug, remdesivir, specifically for COVID-19, and allowed emergency use of three antibody combinations that help the immune system fight the virus. But all the drugs have to be given by IV at hospitals or medical clinics, and demand has been low due to these logistical hurdles.

Health experts have increasingly called for a convenient pill that patients can take themselves when symptoms first appear.

Some drugmakers are testing such medications, but initial results aren’t expected for several more months. The new funds will speed those tests and support private sector research, development and manufacturing.

Last week, the U.S. said it would purchase 1.7 million doses of an experimental antiviral pill from Merck and Ridgeback Biotherapeutics if the pill is shown to be safe and effective. Results from a large study of the drug, molnupiravir, are expected this fall.

Early research suggests the drug may reduce the risk of hospitalization if used shortly after infection by stopping the coronavirus from quickly reproducing. It did not benefit patients who were already hospitalized with severe disease.

Monoclonal antibody treatment is now available to COVID-19 patients, but only about 30% of the delivered doses have been administered.

Several other companies, including Pfizer, Roche and AstraZeneca, also are testing antiviral pills.

The currently available drugs have mostly been shown to help patients avoid hospitalization or shorten their recovery time by several days.

Under former President Trump, the U.S. poured more than $19 billion into rapidly developing multiple vaccines. But less than half that amount went toward developing new treatments.

That shortfall has become increasingly concerning as the vaccination campaign slows and experts emphasize the need to manage the disease among millions of Americans who may never get the shots.

Until this week, the only medicines shown to boost survival were steroids given to patients sick enough to need extra oxygen and intensive care. But on Wednesday, U.K. researchers reported that one of the antibody combinations successfully reduced deaths in a large study of hospitalized COVID-19 patients.


Advertisement